Renal calculi are common, with male predilection and androgen exposure potentially increasing the risk of renal calculi. Systemic effects of androgen deprivation therapy (ADT) have been observed but the influence of ADT on renal calculi in prostate cancer (PCa) patients is not fully understood. We conducted this population-based study to evaluate the impact of ADT on the subsequent risk of renal calculi. We used the National Health Insurance Research Database of Taiwan to analyze the incidences of renal calculi in ADT patients and non-ADT patients from 2001 to 2013. In total, 3309 patients with PCa were selected. After matching with 1:1 propensity-score analysis, 758 ADT patients with 758 matched non-ADT controls were enrolled in the final analysis. Demographic characteristics were analyzed and Cox regression analysis for calculating the hazard ratios (HR) was performed for the subsequent risk of renal calculi. Finally, 186 (186/1516, 12.3%) patients with diagnosed renal calculi were detected. ADT patients had a lower risk of subsequent renal calculi with an adjusted HR of 0.38 (7% vs. 17.5%, 95% confidence interval (CI) 0.28-0.53; p < 0.001) in comparison with the non-ADT group. The Kaplan-Meier curve showed significant differences of cumulative incidences of renal calculi. In conclusion, ADT patients had approximately one-third lower risk of subsequent renal calculi. Further studies are warranted to evaluate the clinical significance.
Keywords: National Health Insurance Research Database; androgen deprivation therapy; prostate cancer; renal calculi; urolithiasis.
Conflict of interest statement
The authors declare no conflict of interest.
No increased risk of psoriasis in patients receiving androgen deprivation therapy for prostate cancer: a 17-year population-based study.Ther Clin Risk Manag. 2018 Sep 28;14:1831-1837. doi: 10.2147/TCRM.S175244. eCollection 2018. Ther Clin Risk Manag. 2018. PMID: 30319264 Free PMC article.
Androgen deprivation therapy and the risk of tenosynovitis in prostate cancer patients.Int Urol Nephrol. 2019 Jul;51(7):1113-1119. doi: 10.1007/s11255-019-02152-y. Epub 2019 May 20. Int Urol Nephrol. 2019. PMID: 31111393
Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases.Prostate Cancer Prostatic Dis. 2019 Sep;22(3):475-482. doi: 10.1038/s41391-019-0130-9. Epub 2019 Jan 28. Prostate Cancer Prostatic Dis. 2019. PMID: 30692587
Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.PLoS One. 2016 Jun 16;11(6):e0157660. doi: 10.1371/journal.pone.0157660. eCollection 2016. PLoS One. 2016. PMID: 27308831 Free PMC article. Review.
Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review.Andrology. 2019 Nov 19. doi: 10.1111/andr.12731. Online ahead of print. Andrology. 2019. PMID: 31743594 Review.